Javier Lacadena

6PUBLICATIONS
21CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 28, 2026
GPA33-Targeted Trimeric Immunotoxin Exhibits Enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.

Javier Ruiz-de-la-Herrán, Javier Narbona, Rubén G Gordo

|Oct 16, 2025
An Innovative Immunotoxin Design Against Allergy Based on the IL-33 Cytokine and the Ribotoxin α-Sarcin.

Javier Narbona, Rodrigo Lázaro-Gorines, Adrián Gutiérrez-Carmona

|Apr 16, 2024
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.

Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona

|Jul 29, 2023
Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.

Javier Narbona, Luisa Hernández-Baraza, Rubén G Gordo

|Feb 25, 2023
A New Optimized Version of a Colorectal Cancer-Targeted Immunotoxin Based on a Non-Immunogenic Variant of the Ribotoxin α-Sarcin.

Javier Narbona, Rubén G Gordo, Jaime Tomé-Amat

|Feb 14, 2022
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña

Pageof 1

Frequent Collaborators

5 joint publications

Javier Narbona

4 joint publications

Laura Sanz

3 joint publications

Rubén G Gordo

2 joint publications

Antonio Tapia-Galisteo